Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

Throughout Gunnar Esiason's journey with cystic fibrosis, the sport of hockey has always been huge part of his family. See ...

At the time of Gunnar's diagnosis, CF patients typically died before reaching ... Gunnar said that after the game, he and his dad shared a moment, knowing that Trikafta was really working and ...

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple ...

Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study.

Vertex's CF franchise remains robust, with TRIKAFTA generating $2.77bn in Q3 ... Barclays set a price target of $509 — and by November, after releasing its Q3 earnings, Vertex stock had achieved ...

“In Phase 3 clinical trials, across a broad range of genotypes, once-daily ALYFTREK demonstrated non-inferiority to TRIKAFTA in ppFEV1 ... monitoring is advised after resuming ALYFTREK.

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis ...

CloseCurlyDoubleQuote; “In Phase 3 clinical trials, across a broad range of genotypes, once-daily ALYFTREK demonstrated non-inferiority to TRIKAFTA in ppFEV1 response ... Closer monitoring is advised ...

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...